Real world data that harnesses deidentified health records is a multi-billion-dollar industry. But what is the value of a ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

Michael Burry's Scion Asset Management ended the first quarter more bullish on companies across different sectors and ...